The Effects of Switch Therapy in Osteoporosis Treatment after Romosozumab after Comparing with Prior Treatment

Table 1

Baseline characteristics by group.

	Naïve group	Teriparatide group	Bisphosphonate group	value
Number	15	15	10
Age (y)	80.9 ± 2.3	80.0 ± 8.4	74.1 ± 6.4	0.055
BMI (kg/m^2)	25.5 ± 6.3	24.9 ± 5.8	24.1 ± 3.8	0.301
BMD: femur (g/cm^2)	0.519 ± 0.150	0.441 ± 0.102^a	0.511 ± 0.001	<0.05^a
BMD: lumbar spine (g/cm^2)	0.709 ± 0.095	0.648 ± 0.144^a	0.693 ± 0.045	<0.05^a
Serum calcium (g/dl)	9.5 ± 0.4	9.6 ± 0.5	9.3 ± 0.3	0.097
eGFR (ml/min/1.73 m^2)	64.3 ± 18.7	62.4 ± 20.1	76.1 ± 12.9	0.053
P1NP (ng/ml)	53.2 ± 18.5	77.5 ± 19.1	16.7 ± 5.4^a	<0.05^a
TRACP-5b (mU/dl)	321.5 ± 116.6	463.0 ± 111.6	211.7 ± 56.9^a	<0.05^a
25OHD (ng/ml)	11.7 ± 6.5	10.0 ± 5.6^a	16.5 ± 5.3	<0.05^a
Previous fracture	None	None	None

Values are expressed as means and standard deviation. ^aANOVA. BMI: body mass index, BMD: bone mineral density, eGFR: estimated glomerular filtration rate, P1NP: procollagen 1 N-terminal propeptide, TRACP-5b: tartrate-resistant acid phosphatase 5b, and 25OHD: 25-hydroxyvitamin D.